3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Head & Neck
2
Genitourinary
2
Endocrine
2
CNS
2
Thoracic
1
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Thyroid Gland Carcinoma
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
Cisplatin
19
Docetaxel
17
Cetuximab
12
Carboplatin
12
Radiotherapy
11
Magnetic Resonance Spectroscopy
10
Biopsy
10
pembrolizumab
9
Paclitaxel
9
Radiotherapy, Intensity-Modulated
8
Immunohistochemistry
8
Erlotinib Hydrochloride
8
Trastuzumab
7
Gemcitabine
7
Chemotherapy, Adjuvant
7
Specimen Handling
6
Radiotherapy, Conformal
5
Radiosurgery
5
Gene Expression Profiling
5
Fluorodeoxyglucose F18
5
Capecitabine
5
Vorinostat
4
Taxes
4
Sorafenib
4
Polymerase Chain Reaction
4
Nivolumab
4
Bevacizumab
4
trastuzumab deruxtecan
3
sargramostim
3
bicalutamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
entrectinib
×
Head & Neck
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA